

ersonal use only



xrf
scientific

Investor Presentation
August 2026

Our Technology

Sample Preparation Technology

Mining and Manufacturing



Minerals:
Iron ore
Gold
Nickel
Copper
Aluminium
Bauxite
Manganese
Uranium
Lithium
Mineral sands
Commercial labs

Materials:
Cement
Metals
Glass
Ceramics
Research
Education

Raw
Samples



Prepared
Samples

Chemical Analysis



Analysis Techniques:
XRF
ICP
Fire Assay
Photon Assay

Our Technology

Sample Analysis Technologies

Chemistry Methods Covered:
Thermogravimetric Analysis
CS/ONH Elemental Analysis
pH Measurement

Orbis Laboratory Crushers

For mineral analysis labs (XRF, ICP, Fire Assay, Photon Assay)

55x Sample Size Reduction

Crushes 110mm drill core samples down to 2mm in a single pass. Industry leading sample crushing times

Automated Sample Splitting

Creates a reference sample for elemental analysis. Eliminates human errors from manual splitting processes

Robust Design

Designed to withstand harsh mining conditions and operate around the clock

Operator Safety

Reduced operator exposure to weight handling risks with automated sample loaders

Lab Products

Sample Preparation Products

For mineral and material analysis labs (XRF, ICP)

X-Ray Flux




Platinum Labware



Recycling service of turning used platinum products into new items

Fusion Machines



Lab Products

Analytical Instruments

XRTGA

Thermogravimetric Analyser

Used for thermal analysis of moisture, volatiles, ash, fixed carbon or loss on ignition

Used in existing mining / construction material industries and new markets such as production quality control of food, plastics and agricultural products

Provides complementary data for the XRF analysis process in materials such as iron ore and cement



Lab Products

Analytical Instruments

CS/ONH Elemental Analysis

Carbon, Sulphur, Oxygen, Nitrogen, Hydrogen

Application examples:

- **Iron, Steel, Cobalt, Nickel, Ferroalloys, Aluminium, Magnesium:** production quality control
- **High strength alloys:** quality control for uses in industries such as space, aviation, military, nuclear energy and biomedical
- **Copper production:** copper grading process
- **Magnetic materials:** rare earth magnet quality control
- **Welding:** prevention of diffusible hydrogen induced weld failure
- **Additive manufacturing:** metal powder quality control
- **More:** minerals, glass, ceramics, cement, case hardening



FY26 Highlights







- Strong demand from mining and industrial customers
- International sales growth in numerous developing markets, in particular Asia
- Continued strong growth in Orbis crusher sales
- Acquired CGA Elemental Analysis Instrument business on 23 April 2026 for upfront consideration of USD \$4m from Bruker AXS SE
- New international offices opened in India and USA
- Positioned Capital Equipment division for significant growth in FY27 through Orbis, xrTGA, new CGA product line and new product releases

FY26 Financial Highlights



- Revenue up 8% to \$64.4m vs FY25
- Adjusted NPBT* up 10% to \$16.1m vs FY25
- NPAT up 1% to \$10.5m vs FY25 after expensing acquisition and new international offices setup/startup costs. Effective tax rate increased to 32% from 29%
- \$11.4m positive operating cashflow
- 49.3% gross margins vs 48.4% in FY25
- Fully franked dividend of 4.5 cents per share
- Record quarterly adjusted profit before tax* of \$4.7m from revenue of \$17.2m during June Q4, driven by strong consumable and Orbis crusher sales, and growth in international sales

**Excludes acquisition costs and setup/startup costs for two new international offices, which were \$0.57m in Q4 and totalled \$0.69m for FY26*



Balance Sheet

(\$m)	2026	2025	Change
Cash and cash equivalents	9.5	12.2	(23%)
Trade and other receivables	9.7	10.3	(5%)
Inventories	21.0	18.8	12%
Other assets	0.7	0.6	19%
Property, plant and equipment	10.9	10.1	8%
PPE lease asset	1.3	1.7	(22%)
Intangible assets	23.9	17.3	38%
Deferred tax asset	1.6	1.8	(13%)
Total assets	78.6	72.8	8%
Trade and other payables			
- platinum loan provisions	0.0	0.7	(100%)
- other items	7.8	7.1	11%
Debt (short-term)	0.2	0.2	0%
Debt (long-term)	0.8	0.9	(18%)
Current lease liabilities	0.7	0.8	(12%)
Non-current lease liabilities	0.7	1.0	(27%)
Income tax liability	1.0	0.9	6%
Deferred tax liability	1.1	1.0	10%
Total liabilities	12.3	12.6	(3%)
Total equity	66.3	60.2	10%

- Net cash position of \$8.5m
- CGA Acquisition was funded 100% in cash and increased:
 - Inventories by \$1.0m
 - Intangible assets by \$6.2m
 - Trade and other payables – other items (acquisition earnout liability) by \$1.4m

Cash Flow Statements

(\$m)	2026	2025
Net cash inflow from operating activities	11.4	10.1
Net cash outflow from investing activities	(8.1)	(2.2)
Net cash outflow from financing activities	(6.0)	(7.7)
Cash at start of period	12.2	12.0
Net increase / (decrease) in cash	(2.7)	0.2
Cash at end of period	9.5	12.2

Highlights:

- Strong operating cashflow conversion above NPAT
- Investing activities: \$5.6m for CGA acquisition
- Financing activities: \$5.0m cash paid out for FY25 dividend (FY24 dividend: \$4.1m)


Consumables

Laboratory consumables and chemicals



(\$m)	FY26	FY25	FY24
Sales revenue	18.1	19.3	18.8
Change in % *	(6%)	2%	11%
NPBT	6.8	7.2	5.7
Change in % *	(6%)	26%	9%
Margin %	38%	38%	30%

* Compared to immediately prior period



Overview for FY26:

- Revenue down 6% on FY25
- NPBT down 6% on FY25
- 2H PBT of \$3.8m vs 1H of \$3.0m due to strong levels of international sales in 2H
- Continued robust demand from the mining sector. Asia continues as a key growth market
- Margin retention driven by international sales growth in numerous developing markets
- Strong incoming order levels in early FY27, driven by international customers


Precious Metals

Platinum laboratory and industrial products



(\$m)	FY26	FY25	FY24
Sales revenue	24.6	21.5	21.5
Change in % *	14%	0%	(1%)
NPBT	4.5	3.5	3.6
Change in % *	27%	(1%)	0%
Margin %	18%	16%	17%

* Compared to immediately prior period



Overview for FY26:

- Revenue** up 14% on FY25
- NPBT up 27% on FY25
- Continued strong demand for recycling sales. Margins expanded, which was driven by high precious metals prices, including platinum and other minor metals used in production
- Platinum price increased significantly during FY26, increasing customer prices for new products and recycling. New product sales reduced in Q2 and Q3, as certain customers became cautious around the timing of their purchases. Demand improved since Q4 as the platinum price reduced

** Revenue is impacted each period by precious metals prices and product sales mix (precious metals vs fabrication revenue)


Capital Equipment

Laboratory instruments and machines



(\$m)	FY26	FY25	FY24
Sales revenue	26.3	22.6	21.8
Change in % *	17%	4%	16%
NPBT	5.3	4.1	4.6
Change in % *	29%	(11%)	35%
Margin %	20%	18%	21%

* Compared to immediately prior period



Overview for FY26:

- Revenue up 17% on FY25
- NPBT up 29% on FY25
- Orbis revenue up 26% on FY25 to \$8.9m. Sales driven by customers in Australia, USA and Canada, predominantly in the gold sector
- Significant expansion of product portfolio through CGA acquisition. Revenue expected to commence in Q2 FY27 once production transferred to Perth. Manufacturing handover commenced in June and is progressing well
- Positive sales momentum for xrTGA with first repeat sales achieved from two large global companies. FY26 sales were \$1m, with the product line expected to grow into a material contributor for the division
- Release of next generation xrFuse 1 and xrFuse 2
- 6+ machines in development, for release through FY27 and beyond

Growth Strategy for FY27

- Implement CGA product line into Perth factory and commence first instrument sales in 1H27. Roll out related consumable sales strategy to existing user base
- Grow Orbis and xrTGA sales in significant addressable markets
- Continue with geographical expansion initiatives such as:
 - Ramp up sales at new offices in India and the US
 - New distributors onboarded as part of CGA acquisition, which can now sell complementary products such as xrTGA
- New product releases, including 6+ machines currently under development:
 - Next generation product upgrades
 - Different size machines or new complementary products
 - Brand-new product ranges
- Expand our portfolio of gold sector analysis products (M&A and internal product developments)
- Continue to pursue M&A opportunities. Our targets are complementary laboratory product manufacturing or supply companies

Corporate Overview

Shareholder Wealth

	EBIT	Earnings Per Share	Dividends Declared Per Share	Share Price	Market Capitalisation
Financial Year	\$	Cents	Cents	\$	\$
2019/20	4,602,319	2.3	1.4	0.24	32,118,193
2020/21	6,818,111	3.8	2.0	0.47	63,916,519
2021/22	8,259,768	4.5	2.5	0.57	77,458,468
2022/23	11,924,806	5.6	3.3	1.17	160,348,236
2023/24	13,470,188	6.4	3.9	1.34	185,757,109
2024/25	14,584,958	7.4	4.5	1.84	258,586,383
2025/26	15,232,366	7.4	4.5	1.73	247,459,335

Directors

Fred Grimwade – Chairman
 Vance Stazzonelli – Managing Director
 David Brown – Non-Executive Director
 David Kiggins – Non-Executive Director

DRP

Please visit www.xrfscientific.com for a copy of the Dividend Reinvestment Plan

Shareholders

Board and Management – 12.3%
 Top 20 – 49.1%

Substantial Shareholders
 David Brown & Glenys Dawn Brown – 5.8%
 Michael Karl Korber – 5.7%

Locations

Head Office – Perth
 Manufacturing – Perth and Melbourne
 International Sales/Service – USA, Canada, Belgium, Germany, India

Capital Structure

Ordinary shares on issue: 143,040,078
 Performance rights: 1,957,868

Contact Information



Tel: (08) 9244 0600
86 Guthrie Street
Osborne Park WA 6017

Vance Stazzonelli – CEO
vance@xrfscientific.com

Disclaimer

No responsibility for contents of Investor Presentation

- To the maximum extent permitted by law, XRF Scientific Limited and representatives:
- make no representation, warranty or undertaking, express or implied, as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient;
- accept no responsibility or liability as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient; and
- accept no responsibility for any errors or omissions from this Investor Presentation whether arising out of negligence or otherwise.

Accuracy of projections and forecasts

- This Investor Presentation includes certain statements, opinions, estimates, projections and forward-looking statements with respect to the expected future performance of XRF Scientific Limited. These statements are based on, and are made subject to, certain assumptions which may not prove to be correct or appropriate. Actual results may be materially affected by changes in economic and other circumstances which may be beyond the control of XRF Scientific Limited. Except to the extent implied by law, no representations or warranties are made by XRF Scientific Limited, its advisers or representatives as to the validity, certainty or completeness of any of the assumptions or the accuracy or completeness of the forward-looking statements or that any such statement should or will be achieved. The forward-looking statements should not be relied on as an indication of future value or for any other purpose.

No offer to sell or invitation to buy

- This Investor Presentation does not, and should not be considered to, constitute or form part of any offer to sell, or solicitation of an offer to buy, any shares in XRF Scientific Limited, and no part of this Investor Presentation forms the basis of any contract or commitment whatsoever with any person.

This Investor Presentation does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not permitted under applicable law. Distribution of this Investor Presentation in or from certain jurisdictions may be restricted or prohibited by law. Recipients must inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. Neither XRF Scientific Limited, its advisers or representatives accept any liability to any person in relation to the distribution or possession of this Investor Presentation from or in any jurisdiction.